Mergers & Acquisitions

Surface Oncology, Inc. (NasdaqGM: SURF)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS).  Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Contingent Value Rights as part of the agreement. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or fill out the form on this page.